9 research outputs found
Decreased ferritin levels, despite iron supplementation, during erythropoietin therapy in anaemia of prematurity
Recombinant human erythropoietin therapy in low-birthweight preterm infants: A prospective controlled study
Reduced immune responses to an aseptic inflammation in mice with congestive heart failure
Erythropoietin (Epo), protein and iron supplementation and the prevention of anaemia of prematurity: effects on serum immunoreactive Epo, growth and protein and iron metabolism
CHANGES IN BLOOD AND RED CELL VOLUME IN THE NEONATAL LAMB AND THE EFFECT OF INSULIN-LIKE GROWTH FACTOR I
Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two Phase 3 randomized, multicenter studies
RationaleIntracerebral haemorrhage caused ˜3 million deaths worldwide in 2015. Two‐thirds of survivors are left dependent on others. Roughly one third of patients are taking antiplatelet drugs at the time of intracerebral haemorrhage in high‐income countries, and this proportion has been increasing over time. Pre‐stroke antiplatelet drug use is associated with a 27% relative increase in one‐month case fatality compared to patients not using antithrombotic drugs. Platelet transfusion, tranexamic acid, and recombinant activated factor VII do not seem to improve outcome after antiplatelet‐associated intracerebral haemorrhage, but desmopressin has seemed promising in non‐randomised pilot studies.ObjectivesWe aim to assess the feasibility of screening, checking the eligibility, approaching, randomising, administering desmopressin or placebo, and completing follow‐up for patients with antiplatelet‐associated intracerebral haemorrhage. DesignWe aim to include 50 patients within 12 hours of spontaneous intracerebral haemorrhage onset, associated with oral antiplatelet drug(s) use in the preceding seven days. Exclusion criteria are: known secondary cause for intracerebral haemorrhage; risk of fluid retention associated with desmopressin; significant hypotension (SBP ConclusionThis is a feasibility trial, which will inform the design of a definitive trial.</div